welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
approved for marketing
The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation
study id #: NCT04337112
condition: Muscular Dystrophy, Duchenne; DMD
status: approved for marketing
purpose:This is an open label expanded access program for boys, 3 to 12 years old, for the treatment of Duchenne muscular dystrophy (DMD) with confirmed mutation(s) in the dystrophin gene that is amenable to skipping of exon 53.
intervention: Viltolarsen
mechanism of action: Exon-skipping to promote dystrophin production
results: https://clinicaltrials.gov/ct2/show/results/NCT04337112
last updated: November 02, 2020
study details
study contacts
rareRelated
-
Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMDThe main objective of this study is to e...
-
Cardiac and Skeletal Muscle Effects in the Randomized HOPE-Duchenne TrialObjective: To assess the feasibility, s...
-
First Patient Enrolled in Mallinckrodt’s Phase 2 Duchenne Muscular Dystrophy TrialMallinckrodt plc, a leading global spec...
-
Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB PatientsThe purpose of this study is to evaluate...
-
A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular DystrophyThis is a multicenter, double blind, pla...
-
Transplantation of Myoblasts to Duchenne Muscular Dystrophy (DMD) PatientsThis Phase I/II of the clinical trial is...
-
Mallinckrodt’s MNK-1411 gets orphan drug status for DMDMallinckrodt plc MNK announced that the ...
-
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical TrialCapricor Therapeutics announced today th...
-
FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular D...FibroGen, Inc., a leading biopharmaceu...
